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Recently, generic drug products have played an increasingly
important role in the health care system globally, especially
in the developing world, as they provide for an effective
and more affordable alternative for healthcare professionals.
Generic drug products are proven therapeutically equivalent
to the corresponding innovator’s product, and hence can be
substituted in clinical practice. The objective of generic drug
development is to develop a stable and bioequivalent generic
drug product with desirable properties in a timely manner.
This presentation is intended to summarize three important
sequential stages essential for successful generic drug devel-
opment based on a regulatory experience in reviewing and
evaluating the Pharmaceutical Development Section (P2) of
the ASEAN Common Technical Dossier (ACTD) of generic drug
product applications submitted to the Food and Drug
Administration, Thailand [1,2]. First, a predevelopment stage
involves collecting and evaluating data and information re-
lating to a drug substance, in particular its physicochemical
properties and critical quality attributes, before implement-
ing any development activities. Also, trade-related information
on a patent or any market exclusivity relating to the innova-
tor’s product should be searched for. Second, development
stages often begin with thorough characterization of the in-
novator’s product, followed by initial compatibility study
between the drug substance and proposed excipients to be
used in the formulation, suitable selection of method for for-
mulation development, and suitable selection of manufacturing
process.
The development stages should result in a model generic
product with in-vitro similarity with the innovator’s product
for a pilot biobatch. Third, once a pilot biobatch of the generic
product is obtained, an in-vivo bioequivalent test should be con-
ducted in accordance with the good clinical practice (GCP) to
assure that the generic product is therapeutically equivalent
to the innovator’s product. Oftentimes, an in-vivo bioequivalent
study presents special challenges for genetic manufacturers,
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particularly for sophisticated dosage forms such as metered-
dose inhaler, locally acting products. Finally, achieving a quality
genetic product requires that generic manufacturers fully un-
derstand and respect for the regulatory environment governing
the development and manufacturing of generic drug prod-
ucts in addition to the science and technical aspects of the
product development. Otherwise, a generic product may fail
during a drug registration process.
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